Emcure Pharmaceuticals Ltd

Emcure Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Emcure Pharmaceuticals Ltd

₹ 1,360 0.60%
15 Jan 2:48 p.m.
emcure.co.in BSE: 544210 NSE: EMCURE
About

Incorporated in 1981, Emcure Pharmaceuticals
Ltd manufactures and markets pharmaceutical products globally[1]

Key Points

Business Overview:[1][2]
EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.

Website BSE NSE
  • Market Cap ₹ 25,753 Cr.
  • Current Price ₹ 1,360
  • High / Low ₹ 1,580 / 1,225
  • Stock P/E 159
  • Book Value ₹ 150
  • Dividend Yield 0.00 %
  • ROCE 10.3 %
  • ROE 8.60 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 19.1%

Cons

  • Stock is trading at 9.04 times its book value
  • The company has delivered a poor sales growth of 7.35% over past five years.
  • Company has a low return on equity of 13.6% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE IPO Nifty 500 Nifty 500 Multicap 50:25:25 Nifty MidSmallcap 400 Nifty Smallcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Mar 2024 Jun 2024 Sep 2024
837 888 903 970 1,105
725 788 796 855 952
Operating Profit 111 100 106 115 152
OPM % 13% 11% 12% 12% 14%
21 30 25 33 55
Interest 39 46 39 38 31
Depreciation 46 48 56 55 56
Profit before tax 48 36 35 55 119
Tax % 24% 24% 18% 27% 27%
36 27 29 40 87
EPS in Rs 2.00 1.51 1.60 2.23 4.60
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
2,454 2,376 3,107 3,387 3,107 3,498
1,883 1,948 2,367 2,593 2,668 3,056
Operating Profit 570 428 740 795 439 442
OPM % 23% 18% 24% 23% 14% 13%
56 89 90 133 119 129
Interest 127 137 118 145 167 166
Depreciation 130 155 154 166 179 205
Profit before tax 370 225 558 616 212 200
Tax % 23% 22% 25% 28% 25% 20%
284 175 420 447 160 161
EPS in Rs 15.68 9.69 23.25 24.71 8.85 8.88
Dividend Payout % 16% 0% 4% 12% 23% 23%
Compounded Sales Growth
10 Years: %
5 Years: 7%
3 Years: 4%
TTM: 13%
Compounded Profit Growth
10 Years: %
5 Years: -12%
3 Years: -27%
TTM: -1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 14%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 181 181 181 181 181 181 189
Reserves 1,597 1,734 2,121 1,532 1,661 1,754 2,639
1,224 1,243 1,603 1,579 1,773 1,595 824
576 713 958 1,032 1,001 1,226 1,488
Total Liabilities 3,578 3,871 4,863 4,323 4,616 4,757 5,140
1,100 1,166 1,147 1,151 1,433 1,718 1,670
CWIP 406 326 192 239 253 106 150
Investments 311 408 864 563 690 684 684
1,761 1,971 2,660 2,369 2,240 2,248 2,636
Total Assets 3,578 3,871 4,863 4,323 4,616 4,757 5,140

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
371 385 775 428 505
-276 -169 -836 -394 -271
-53 -46 31 -343 -55
Net Cash Flow 42 170 -30 -309 180

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 135 175 117 109 124 115
Inventory Days 243 200 183 202 214 206
Days Payable 159 197 169 166 203 220
Cash Conversion Cycle 220 177 131 144 135 101
Working Capital Days 131 146 97 132 127 100
ROCE % 13% 19% 21% 11% 10%

Shareholding Pattern

Numbers in percentages

Sep 2024
78.08%
2.91%
3.96%
15.05%
No. of Shareholders 1,52,914

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls